Loading
Life sciences · Journal article
World Journal of Pharmaceutical Research · August 16, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an uncontrolled case report of a single 45-year-old man with Grade 2 fatty liver who received Ayurvedic treatment (Shamana therapy, Virechana, Snehapana, Deepana-Pachana) for 60 days and reported improvement in liver enzymes, hepatic fat, and lipid profile. The absence of a control group, blinding, or objective adjudication of outcomes means the contribution of the intervention itself cannot be separated from natural history, placebo effect, or concurrent lifestyle changes.
Single uncontrolled case report. One 45-year-old man with Grade 2 fatty liver.. Intervention: Ayurvedic therapy regimen: Shamana therapy with hepatoprotective herbs, Virechana, Snehapana, and Deepana-Pachana over 60 days. n = 1.
45-year-old man with Grade 2 fatty liver on ultrasound and liver function tests received Ayurvedic therapy for 60 days After treatment: lipid profile improved, hepatic fat decreased, liver enzyme levels returned to normal, clinical symptoms significantly improved
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case does not establish that Ayurvedic therapy is effective for fatty liver disease. A single uncontrolled observation cannot guide clinical practice; clinicians should rely on controlled trials to evaluate any intervention for fatty liver disease.
A single uncontrolled case report with no comparator, no blinding, and no statistical analysis; describes clinical improvement in one patient but cannot establish efficacy or rule out natural history.
As stated by the source record.
Quoted from the source exactly as published.
This case does not establish that Ayurvedic therapy is effective for fatty liver disease. A single uncontrolled observation cannot guide clinical practice; clinicians should rely on controlled trials to evaluate any intervention for fatty liver disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The reason for a major global public health concern is rising rates of obesity, sedentary lifestyles, poor eating habits, and metabolic syndrome, fatty liver disease (FLD). FLD is caused by increasing the level of lipids, especially triglycerides, within hepatocytes. If not treated this condition can develop into cirrhosis fibrosis, non-alcoholic steatohepatitis, and in extreme cases, hepatocellular cancer. Initially it does not show any symptoms, but patients may feel systemic metabolic abnormalities, mild dyspepsia, weariness, and heaviness in the right hypochondrium. Instead than treating the metabolic and intestinal abnormalities, modern care generally relies on pharmacological interventions, dietary restrictions, exercise, and lifestyle changes. In Ayurveda, FLD can be correlated with Yakrit Vikar or Medo Yakrit Vriddhi, a condition arising due to Kapha-Pitta predominance, Meda Dhatu vitiation, impaired Agni (digestive fire), and accumulation of Ama (metabolic toxins). Blockage in yakrit and medovaha srotas causes Fatty infiltration along with systemic metabolic dysfunction. In this case report describes a 45 year old man who has diagnosed with Grade 2 fatty liver based on liver function tests and ultrasound and then taken Ayurvedic therapy regimen for 60 days. Shamana therapy using hepatoprotective herbs, Virechana for purgation, Snehapana for internal oleation, and Deepana-Pachana to enhance Agni. The patient's reports have improved after the treatment, lipid profile improved, hepatic fat decreased, liver enzyme levels returned to normal, and clinical symptoms significantly improved. This study demonstrates the potential of Ayurveda as an effective supplementary medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.